Locoregional Treatment of Malignant Hepatic Tumors with Biologic Response Modifiers

Surgical Oncology Clinics of North America

Volumn 17, Issue 4, 2008, Pages 935-955

  Yamamoto, Akira ^a,b   Sato, Takami ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CARBOPLATIN; CARMUSTINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; MELPHALAN; MITOMYCIN C; PICIBANIL; SORAFENIB; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CHEMOEMBOLIZATION; COLORECTAL CANCER; DENDRITIC CELL; DRUG DOSE COMPARISON; GENE THERAPY; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; IMMUNOMODULATION; IMMUNOSTIMULATION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MONOTHERAPY; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CALCIFICATION; REVIEW; SCLEROTHERAPY; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LIVER NEOPLASMS;

EID: 49649112598     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.04.001     Document Type: Review

References (108)

1. Coley W.B. A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. Post-Graduate 8 (1893) 278-286
2. Kolmel K.F., Vehmeyer K., Gohring E., et al. Treatment of advanced malignant melanoma by a pyrogenic bacterial lysate. A pilot study. Onkologie 14 (1991) 411-417
3. Kountouras J., and Lygidakis N.J. New epidemiological data on liver oncogenesis. Hepatogastroenterology 47 (2000) 855-861
4. Moradpour D., and Wands J.R. Molecular pathogenesis of hepatocellular carcinoma. In: Zakim D., and Boyer T.D. (Eds). Hepatology: a textbook of liver disease. 4th edition (2003), W.B. Saunders, Vol. 2. Philadelphia 44:1333-54
5. Okuda K. Hepatocellular carcinoma. J Hepatol 32 (2000) 225-237
6. Bosch F.X., Ribes J., and Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 19 (1999) 271-285
7. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
8. Fan S.T., Ng I.O., Poon R.T., et al. Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival. Arch Surg 134 (1999) 1124-1130
9. Ikai I., Yamamoto Y., Yamamoto N., et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am 12 (2003) 65-75
10. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
11. Johnson P.J. Are there indications for chemotherapy in hepatocellular carcinoma?. Surg Oncol Clin N Am 12 (2003) 127-134
12. Belghiti J., Panis Y., Farges O., et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214 (1991) 114-117
13. Nagasue N., Uchida M., Makino Y., et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 105 (1993) 488-494
14. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). 2007 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol 25 (2007) LBA1
15. Wada Y., Nakashima O., Kutami R., et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27 (1998) 407-414
16. Dizon D.S., and Kemeny N.E. Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol 29 (2002) 126-135
17. Kemeny N.E., and Atiq O.T. Non-surgical treatment for liver metastases. Baillieres Best Pract Res Clin Gastroenterol 13 (1999) 593-610
18. Gennari L. Liver metastases: a many-sided therapeutic problem. Hepatogastroenterology 39 (1992) 5-9
19. Hao C.Y., and Ji J.F. Surgical treatment of liver metastases of colorectal cancer: strategies and controversies in 2006. Eur J Surg Oncol 32 (2006) 473-483
20. Kemeny N., Brown K., Covey A., et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17 (2006) 1214-1224
21. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
22. Feldman E.D., Pingpank J.F., and Alexander H.R. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 11 (2004) 290-297
23. Gragoudas E.S., Egan K.M., Seddon J.M., et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 98 (1991) 383-390
24. Soni S., Lee D.S., DiVito Jr. J., et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol 24 (2002) 488-491
25. Patel K., Sullivan K., Berd D., et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 15 (2005) 297-304
26. Bedikian A.Y., Legha S.S., Mavligit G., et al. Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 76 (1995) 1665-1670
27. Canning C., O'Brien M., Hegarty J., et al. Liver immunity and tumor surveillance. Immunol Lett 107 (2006) 83-88
28. Malter M., Friedrich E., and Suss R. Liver as a tumor cell killing organ: Kupffer cells and natural killers. Cancer Res 46 (1986) 3055-3060
29. Bowen D.G., McCaugphan G.W., and Bertolino P. Intrahepatic immunity: a tale of two sites?. Trends Immunol 26 (2005) 512-517
30. Knolle P.A., and Gerken G. Local control of the immune response in the liver. Immunol rev 174 (2000) 21-34
31. Crispe I.N. Hepatic T cells and liver tolerance. Nat Rev Immunol 3 (2003) 51-62
32. Goddard S., Youster J., Morgan E., et al. Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am J Pathol 164 (2004) 511-519
33. Berg M., Wingender G., Djandji S., et al. Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance. Eur J Immunol 36 (2006) 2960-2970
34. Bouwens L., Jacobs R., Remels L., et al. Natural cytotoxicity of rat hepatic natural killer cells and macrophages against a syngeneic colon adenocarcinoma. Cancer Immunol Immunother 27 (1988) 137-141
35. Bouwens L., Marinelli A., Kuppen P.J., et al. Electron microscopic observations on the accumulation of large granular lymphocytes (pit cells) and Kupffer cells in the liver of rats treated with continuous infusion of interleukin-2. Hepatology 12 (1990) 1365-1370
36. Gold P.J., Thompson J.A., Markowitz D.R., et al. Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J Sci Am 3 (1997) S85-S91
37. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210 (1989) 474-484
38. Lygidakis N.J., Kosmidis P., Ziras N., et al. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 15 (1995) 467-472
39. Lygidakis N.J., Ziras N., and Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 42 (1995) 155-161
40. Lygidakis N.J., Pothoulakis J., and Konstantidou A.E. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 15 (1995) 543-550
41. Lygidakis N.J., Stringaris K., Kokinis K., et al. Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study. Hepatogastroenterology 43 (1996) 212-220
42. Okuno K., Shigeoka H., Lee Y.S., et al. Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases. Hepatogastroenterology 43 (1996) 688-691
43. Okuno K., Kaneda K., and Yasutomi M. Regional IL-2-based immunochemotherapy of colorectal liver metastases. Hepatogastroenterology 46 (1999) 1263-1267
44. Boura P., Kountouras J., Lygidakis N.J., et al. Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters. Hepatogastroenterology 46 (1999) 799-803
45. Libutti S.K., Barlett D.L., Fraker D.L., et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 191 (2000) 519-530
46. Alexander H.R., Libutti S.K., Bartlett D.L., et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 6 (2000) 3062-3070
47. Bartlett D.L., Libutti S.K., Figg W.D., et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129 (2001) 176-187
48. Lygidakis N.J., Sgourakis G., Vlachos L., et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 48 (2001) 1685-1691
49. Feldman E.D., Wu P.C., Beresneva T., et al. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 8 (2004) 200-207
50. Lygidakis N., Singh G., Bardaxoglou E., et al. New frontiers in the management of advanced hepatocellular carcinoma. "A new look to an old problem.". Hepatogastroenterology 51 (2004) 62-67
51. Pohlen U., Rieger H., Mansmann U., et al. Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patients with non-resectable colorectal liver metastases. Anticancer Res 26 (2006) 3957-3964
52. Maguire H.C., and Ettore V.L. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 48 (1967) 39-43
53. Micheau O., Solary E., Hammann A., et al. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89 (1997) 783-789
54. Krown S.E. Interferons in malignancy: biological products or biological response modifiers?. J Natl Cancer Inst 80 (1988) 306-309
55. Thomas H., and Balkwill F.R. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther 52 (1991) 307-330
56. Bose A., and Baral R. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity. Immunol Lett 108 (2007) 68-77
57. Slaton J.W., Perrotte P., Inoue K., et al. Interferon-alfa-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 2726-2734
58. Uehara H. Angiogenesis of prostate cancer and antiangiogenic therapy. J Med Invest 50 (2003) 146-153
59. Lai C.L., Wu P.C., Lok A.S., et al. Recombinant alpha 2 interferon is superior to doxorubin for inoperable hepatocellular carcinoma: a prospective randomized trial. Br J Cancer 60 (1989) 928-933
60. Llovet J.M., Sala M., Castells L., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31 (2000) 54-58
61. Lans T.E., Bartlett D.L., Libutti S.K., et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 7 (2001) 784-790
62. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
63. Yamada R., Sato M., Kawabata M., et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148 (1983) 397-401
64. Carrasco C.H., Charnsangavej C., Ajani J., et al. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147 (1986) 149-154
65. Tellez C., Benson A.B., Lyster M.T., et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82 (1998) 1250-1259
66. Lin G., Lunderquist A., Hagerstrand I., et al. Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 96 (1984) 517-526
67. Kobayashi N., Ishii M., Ueno Y., et al. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 19 (1999) 25-31
68. Kanai T., Monden M., Sakon M., et al. New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemotherapy and Pharmacology 33 Suppl (1994) S48-S54
69. Okamoto M., Oshikawa T., Tano T., et al. Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 29 (2006) 78-86
70. Yoshida T., Sakon M., Umeshita K., et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma. J Clin Gastroenterol 32 (2001) 59-65
71. Yuen M.F., Ooi C.G., Hui C.K., et al. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 97 (2003) 2776-2782
72. Bot F.J., van Eijk L., Schipper P., et al. Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates immature marrow precursors but no CFU-GM, CFU-G, or CFU-M. Exp Hematol 17 (1989) 292-295
73. Grabstein K.H., Urdal D.L., Tushinski R.J., et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232 (1986) 506-508
74. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
75. Sato T. Locoregional immuno(bio)therapy for liver metastases. Semin Oncol 29 (2002) 160-167
76. Sato T., Terai M., Huandong Y., et al. Systemic immune response after immunoembolization of liver metastasis with granulocyte-macrophage colony stimulating factor (GM-CSF). Proc Am Assoc Cancer Res 43 (2002) 914
77. Yamamoto A., Chervoneva I., Sullivan K., et al. Prognostic factors for survival after embolization of hepatic metastases in uveal melanoma. 2007 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol 25 (2007) 8562
78. Kradin R.L., Kurnick J.T., Lazarus D.S., et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1 (1989) 577-580
79. Rosenberg S.A., Lotze M.T., Muul L.M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin alone. N Engl J Med 316 (1987) 889-897
80. Basse P., Herberman R.B., Nannmark U., et al. Accumulation of adoptively transferred A-LAK cells in metastases. J Exp Med 174 (1991) 479-488
81. Fisher B., Packard B.S., Read E.J., et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7 (1989) 250-261
82. Takashima K., Fujiwara H., Inada S., et al. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases. Anticancer Res 26 (2006) 3327-3332
83. Matsuhashi N., Moriyama T., Nakamura I., et al. Adoptive immunotherapy of primary and metastatic liver cancer via hepatic artery catheter. Eur J Cancer 26 (1990) 1106-1107
84. Komatsu T., Yamauchi K., Furukawa T., et al. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. J Clin Immunol 10 (1990) 167-174
85. Okino T., Kan N., Nakanishi M., et al. The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer. J Cancer Res Clin Oncol 116 (1990) 197-202
86. Takayama T., Makuuchi M., Sekine T., et al. Distribution and therapeutic effect of intraarterially transfused tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Cancer 68 (1991) 2391-2396
87. Satoh K., Kan N., Okino T., et al. The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from gastric and colorectal cancers. Biotherapy 6 (1993) 41-49
88. Keilholz U., Scheibenbogen C., Brado M., et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 30A (1994) 103-105
89. Hannemann B., Scheibenbogen C., Schumichen C., et al. Intrahepatic adoptive immunotherapy with autologous tumor cytotoxic macrophages in patients with cancer. J Immunother Emphasis Tumor Immunol 18 (1995) 19
90. Kawata A., Une Y., Hosokawa M., et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Am J Clin Oncol 18 (1995) 257-262
91. Ferlazzo G., Scisca C., Iemmo R., et al. Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. J Immunother 20 (1997) 158-163
92. Ueda Y., Yamagishi H., Tanioka Y., et al. Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology 46 Suppl 1 (1999) 1274-1279
93. Kobari M., Egawa S., Shibuya K., et al. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br J Surg 87 (2000) 43-48
94. Kumagi T., Akbar S.M., Horiike N., et al. Administration of dendritic cells in cancer nodules in hepatocellular carcinoma. Oncol Rep 14 (2005) 969-973
95. Chi K.H., Liu S.J., Li C.P., et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28 (2005) 129-135
96. Nakamoto Y., Mizukoshi E., Tsuji H., et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 147 (2007) 296-305
97. Rubin J., Galanis E., Pitot H.C., et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogenic histocompatibility antigen, HLA-B7. Gene Ther 4 (1997) 419-425
98. Sangro B., Mazzolini G., Ruiz J., et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22 (2004) 1389-1397
99. Atencio I.A., Grace M., Bordens R., et al. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a phase I colorectal cancer trial. Cancer Gene Ther 13 (2006) 169-181
100. Guan Y.S., Sun L., Zhou X.P., et al. Combination therapy with recombinant adenovirus-p53 injection (rAd-p53) via transcatheter hepatic arterial chemoembolization for advanced hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 13 (2003) 125-127
101. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum gene ther 16 (2005) 1016-1027
102. Hernandez-Alcoceba R., Sangro B., and Prieto J. Gene therapy of liver cancer. World J Gastroenterol 12 (2006) 6085-6097
103. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 70 (1998) 83-243
104. Mazzolini G., Qian C., Narvaiza I., et al. Adenoviral gene transfer of interleukin-12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther 11 (2000) 113-125
105. Leonard J.P., Sherman M.L., Fisher G.L., et al. Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-gamma production. Blood 90 (1997) 2541-2548
106. McLoughlin J.M., McCarty T.M., Cunningham C., et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 12 (2005) 825-830
107. Abrams S.I. Role of anti-CTLA-4 therapies in the treatment of cancer. Curr Opin Mol Ther 6 (2004) 71
108. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of CTLA-4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100 (2003) 4712-4717